About Us

Over 30 years ago, our founder pioneered the development of the first device capable of precisely controlling oxygen levels in an incubator. This simple innovation revealed a critical gap in cell processing technology: existing methods were unable to provide cells with physiologically relevant conditions. This realization became the cornerstone of the Biospherix® platform.

Addressing this critical need led to the creation of the Xvivo System®, a modular and portable aseptic space designed to envelop entire protocols in an optimal, continuously controlled environment. With customizable modules and design, the Xvivo System® seamlessly accommodates diverse cell production processes and readily adapts to protocol adjustments and dynamic pipelines.

The introduction of this groundbreaking technology has catalyzed transformative advancements in drug design, medicine, and cell therapies. Users have experienced revolutionary improvements in their data by processing cells within a fully physiological environment for the first time, marking a profound shift in scientific and medical capabilities.

Read Our Science

Meet the team

Randy Yerden

Founder

While working as a laboratory technician at the University of Rochester, Randy created the first device to control oxygen sensing in an incubator. What was intended to be a singular invention quickly gained traction as other labs and colleagues saw the benefits of physiologic oxygen control and began requesting that Randy create similar devices for their studies. Within a few years, BioSpherix Ltd. was born, and with it a revolutionary approach to cell processing. 30 years later, Randy, though now retired, serves as a consultant for the business that he created while enjoying the peace that comes with settling down after a long and fruitful career.

Ahmed Mustafa, MBA

President, Chief Executive Officer

Inspired by the transformative science behind BioSpherix’s core technology, Ahmed joined the company in 2024 with goals to reinvigorate the company strategy. Endowed with experience from a multitude of industries including science education, toxicology, emergency medicine, and more, Ahmed utilizes his leadership to propel BioSpherix into a new era of growth and innovation. His leadership is characterized by a commitment to regenerating and fostering collaboration internally amongst employees and externally with company partners, all towards the goal of advancing the company mission to revolutionize the biotechnology landscape.

Greg Pratt

Chief Operating Officer

Greg is one of BioSpherix’s veteran employees, starting his journey as a Manager and Network Administrator in 2001. His dedication to the company shines bright in his continued promotion of company culture and demonstrated abilities in business development, service, and policy.

Ann Stacy

Chief Financial Officer

Ann joined BioSpherix in 2017 armed with a multitude of leadership endeavors including Town Supervisor and Adjunct Professor of Accounting. Her rounded expertise in finance and people-management suits her well in her role as both BioSpherix’s CFO and Human Resources manager.

Alicia Henn, PhD MBA

Chief Scientific Officer

Dr. Henn came to BioSpherix in 2013 with a background in cancer and immunology research. She works to improve scientific reproducibility through cloneable, physiologically relevant cell environments. Dr. Henn also owns the In Vitro Reproducibility and Physiologic Cell Manufacturing groups on LinkedIn.